Merck quarterly earnings beat forecasts

"background-image:url('http://l.yimg.com/bt/api/res/1.2/byMwIBwmZH.BMPX6i4l_1w--/YXBwaWQ9eW5ld3M7Y2g9MzAyO2NyPTE7Y3c9NDUwO2R4PTA7ZHk9MDtmaT11bGNyb3A7aD0xMjg7cT04NTt3PTE5MA--/http://media.zenfs.com/en_us/News/Reuters/2012-07-27T112411Z_1_CBRE86Q0VOO00_RTROPTP_2_SCHERINGPLOUGH-MERCK.JPG');" width

View the Original article

GSK's new once-daily HIV drug matches Merck rival

/AIDS business - an area of medicine it used to dominate but where it has fallen behind rivals in recent years. ...","exp":"","source":"y.newssocialchrome"

View the Original article

Merck ponders next step for troubled heart drug

Officials at drugmaker Merck & Co. say they will take more time to decide what to do about an experimental blood thinner that gave disappointing results in a second big study.

The study was aimed at preventing repeat heart attacks and strokes in people who had already suffered one or were in danger of one because of hardened arteries in their legs.

The drug, vorapaxar, lowered the risk of those problems but also raised the risk of major bleeding, including dangerous bleeding in the head, which largely canceled out the drug's benefit.

Results of the study were discussed Saturday at an American College of Cardiology conference in Chicago and published by the New England Journal of Medicine.

Merck had hoped vorapaxar would become a new, first-of-its-kind blood thinner.

The company-sponsored study involved more than 26,000 patients in 32 countries. All were given usual heart medicines plus aspirin, and half also received daily vorapaxar pills.

Safety monitors stopped part of the study last year after seeing higher rates of bleeding in the head among people with a history of stroke who were on the experimental drug. The study continued in the rest of the participants.

After three years, about 9 percent of those given vorapaxar had suffered a heart attack or a stroke or had died from heart-related causes versus more than 10 percent of those not given the drug. Moderate or severe bleeding occurred in about 4 percent of those on vorapaxar versus just more than 2 percent of the others, said the study's leader, Dr. David Morrow of Brigham and Women's Hospital in Boston.

Among those with a history of heart attack

View the Original article

Merck blood thinner shows mixed results: study

"An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers say. The drug could reduce the risk of dying from a future heart attack or stroke by as much as 20 percent in people who had a previous heart attack, but it also significantly hiked the risk of hemorrhage. (AFP Photo/Tom Mihalek)" title

View the Original article